hepatyrix
Vaccineexperimental
Hepatitis A and typhoid vaccine is a combination vaccine to protect against the infectious diseases hepatitis A and typhoid. It is a combination of inactivated Hepatitis A virus and Vi polysaccharide of Salmonella typhi bacteria. Branded formulations include Hepatyrix from GlaxoSmithKline, and ViVaxim and ViATIM from Sanofi Pasteur. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started May 1, 2002 (NCT00197249)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Salmonella typhimuriumImmunity, active
Salmonella typhimurium immunity, active
- Hepatitis A virusImmunity, active
Hepatitis A virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaHepatitis A and typhoid vaccine ↗
Also known as
- hepatyrix
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00197249 | Phase 3 | May 1, 2002 | GlaxoSmithKline |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2002 |
1 organizations
Page 1 / 1